FRANKFURT, Oct 29 (Reuters) - Novartis (NOVN.S), opens new tab raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but its shares fell ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

The Swiss pharmaceutical firm now forecasts 2024 core operating income growth of a high-teens percentage, compared with its previous target of a mid- to high-teens percentage. Novartis now ...

For pharma companies, the goldilocks earnings scenario is a strong quarterly beat paired with a promising pipeline of innovative drugs. This balance is crucial for the industry, where firms face the ...

Swiss pharmaceutical giant Novartis raised its 2024 financial targets Tuesday after posting rising sales and margins in the ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

Swiss pharmaceutical giant Novartis will pay Monte Rosa Therapeutics $150 million upfront payment for a global license to develop, manufacture and sell some drug candidates, the U.S.-based biotech ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small ...

Basel, October 18, 2024 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...